Page 274 - 2021_05-Haematologica-web

Letters to the Editor
the treatment assignment and RUNX1-RUNX1T1 status (RFS: P=0.300; EFS: P=0.383; OS: P=0.391). All patients with CBFB-MYH11 AML achieved complete remission after both intermediate-dose and conventional-dose cytarabine. We were unable to determine the impact of intermediate-dose cytarabine in patients with CBFB- MYH11 AML since there were only 33 patients with CBFB-MYH11 in our cohort.
In this subgroup analysis of our trial, our data suggested
that AML patients with RUNX1-RUNX1T1 benefited from intermediate-dose cytarabine induction. Previous reports also indicated that a higher dose of cytarabine improved the outcome in patients with RUNX1-RUNX1T1 AML.14,15 Hence, all these data suggest that an induction regimen with an intensified dose of cytarabine benefits patients with RUNX1-RUNX1T1 AML.
There were a total of 89 patients with NPM1 mutations, regardless of FLT3-ITD mutation status, in our cohort,
AD
BE
CF
Figure 3. Outcomes of NPM1 and FLT3-ITD mutant acute myeloid leukemia by treatment assignment. (A) Relapse-free survival, (B) event-free survival, and (C) overall survival of patients with NPM1 mutations. (D) Relapse-free survival, (E) event-free survival, and (F) overall survival of patients with FLT3-ITD mutation. HR: hazard ratio; 95%CI: 95% confidence interval.
1494
haematologica | 2021; 106(5)